Basics of Immunotherapy
Potential Therapeutic Targets
Common Checkpoint Molecules in Immunotherapy
Nivolumab
Pembrolizumab
Toxicity With Checkpoint Inhibitors
Key Points Regarding Toxicity
Considerations for Toxicity Management
Completed Studies With First-Line Checkpoint Inhibitors
First-Line Anti-PD-L1: Durvalumab
CheckMate 012 Efficacy Results
CheckMate 012 Safety Results
CheckMate 568
KEYNOTE-021 Design
KEYNOTE-021 Efficacy Results
KEYNOTE-021 Safety Results
Other Treatment Considerations
POPLAR Study Outcomes
Additional Combination Studies
PD-L1 Testing
IFNγ as a Biomarker in Durvalumab in NSCLC
Additional Second-Line Checkpoint Inhibitor Combination Studies
Concluding Remarks
Abbreviations
Abbreviations